Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Bulent Ozpolat · METHODIST HOSPITAL RESEARCH INSTITUTE · 2024 · $378,124 — Project Summary Triple-negative breast cancer (TNBC) has the highest patient death rate of all breast cancer subtypes. Several molecular targets have been identified for breast cancer treatment, but currently, there is no approved, broadly applicable targeted therapy for TNBC. Through 10 years of re…
JANICE CHOU · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · 2024 · $2,208,533 — Clinically, GSD-Ib patients manifest a metabolic phenotype of impaired blood glucose homeostasis and a long-term risk of hepatocellular adenoma/carcinoma (HCA/HCC). The etiology of HCA/HCC in GSD-Ib is unknown. Studies have shown that deficiency in autophagy, contributes to hepatocarcinogenesis. Aut…
Santanu Raychaudhuri · NEOVAXSYN, INC. · 2024 · $2,000,000 — Particle-based Co-Delivery of HIV Immunogens as Next-Generation HIV Vaccines: A major focus of HIV vaccine research has been the development of immunogens that elicit broadly neutralizing antibody responses targeting the envelope protein (Env). While the field has predominantly focused on immunogen …
Sharan Kumar Reddy Bobbala · WEST VIRGINIA UNIVERSITY · 2024 · $264,870 — B-cell acute IympnooIast1c IeuKemIa (ALL) accounts for 75% of all ALL diagnoses. Specifically, treating the Philadelphia {Ph) chromosome subgroup (which creates a new gene called BCR-ABL) of B-cell ALL challenging and has high relapse rates and poor survival. Mounting evidence from recent findings s…
David M Gamm · UNIVERSITY OF WISCONSIN-MADISON · 2024 · $2,008,538 — PROJECT SUMMARY/ABSTRACT – FOLLOWER PROJECT 2 Best Disease (BD) is a prevalent, primarily autosomal dominant, macular degenerative disorder that results in retinal pigment epithelium (RPE) dysfunction and progressive loss of central vision. BD results from >200 known missense mutations in the BEST1 …
ROBERT H CARNAHAN · VANDERBILT UNIVERSITY MEDICAL CENTER · 2024 · $5,228,898 — PROJECT SUMMARY - CORE D The Vaccine and Therapeutics Technologies (VTT) Core will focus on developing a rapid pipeline for next- generation vaccine and therapeutic antibody candidates. We will facilitate this by providing critical reagents, consulting, and coordinating production and quality contro…
Michael J Sailor · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2024 · $684,136 — PROJECT SUMMARY New strategies to combat pneumonia caused by different pathogens are urgently needed. Inflammatory macrophages play an essential role in clearing bacteria, fungi, and viruses during infections; however, hyperinflammatory responses mediated by these cells can cause severe side effects…
Shuxia Wang · UNIVERSITY OF KENTUCKY · 2024 · $459,040 — Obesity is an independent risk factor for development of non-alcoholic fatty liver disease (NAFLD). With the epidemic burden of obesity and metabolic diseases, NAFLD occurrence is steadily rising, along with the need for therapeutic options of this disease. Preliminary data from rodent and human stu…
Olga Gursky · BOSTON UNIVERSITY MEDICAL CAMPUS · 2024 · $296,685 — Amyloid diseases afflict 10 million patients worldwide. This project is focused on AA amyloidosis, a life-threatening complication of chronic inflammation wherein deposition of serum amyloid A (SAA), and its fragments causes kidney and liver damage and, if untreated, death. There is no cure for AA a…
Luiz Miguel Quinn Camargo · UBIQUITX, INC. · 2024 · $306,872 — PROJECT SUMMARY Pharmacologically targeting intracellular proteins is a key challenge of modern drug development, requiring innovation and the development of new technologies. This challenge is made more difficult by the fact that many protein targets remain beyond the reach of established drug disc…
Efstathios Karathanasis · CASE WESTERN RESERVE UNIVERSITY · 2024 · $561,099 — PROJECT SUMMARY First-line chemotherapy is the standard of care for patients with triple-negative breast cancer (TNBC). While short-term response is achievable, most patients succumb to recurrence due to metastasis. Micrometastasis encompasses a small population of dormant disseminated tumor cells (…
Robert E Fleming · SAINT LOUIS UNIVERSITY · 2024 · $679,795 — ABSTRACT The overall goal of our proposal is to investigate how iron metabolism and erythropoietic activity are interrelated, and the mechanisms whereby dysregulation in one contributes to pathophysiology in the other. Roles for the two transferrin receptors in these processes is clear; however, lit…
Ashok Kumar · WAYNE STATE UNIVERSITY · 2024 · $453,470 — Project Summary Bacterial endophthalmitis is a vision-threatening complication of eye surgeries and ocular trauma. The vision loss in endophthalmitis occurs due to uncontrolled inflammation-mediated retinal tissue damage. The long-term goal of our research has been to study the pathobiology of endop…
Prabhani Atukorale · UNIVERSITY OF MASSACHUSETTS AMHERST · 2024 · $198,981 — PROJECT SUMMARY This proposal seeks to develop a targeted tri-agonist “super adjuvant” nanoparticle platform for in situ cancer vaccination. Vaccines consist of 2 components: a tumor-specific antigen that is recognized by CD8+ cytotoxic T cells (CTLs) and an adjuvant that provides the necessary cost…
Angela Meier · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2024 · $1,009,268 — PROJECT SUMMARY Pneumonia is the most common cause of hospitalization due to infection in the US and the most common cause of infection-related death. Mortality in healthcare-associated pneumonia (HAP) is 13% overall and 36% in patients admitted to the ICU. Bacterial lung infections are also a frequ…
William H. Gmeiner · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2024 · $549,986 — PROJECT SUMMARY Metastatic colorectal cancer (mCRC) remains highly lethal despite decades of optimizing 5-fluorouracil (5-FU)- based combination chemotherapy regimens that are central to treatment. The causes of treatment failure with 5-FU-based regimens include decreased metabolism to FdUMP, the pr…
Yifang Xie · UNIV OF NORTH CAROLINA CHAPEL HILL · 2024 · $106,201 — Project Summary Heart attacks, or myocardial infarctions (MI), remain a leading cause of death worldwide. As adult human hearts have limited regenerative capacity, cardiomyocytes (CMs) lost after MI are replaced by fibrotic scar tissue, leading to cardiac dysfunction and often heart failure. A promi…
Sheung Chee Thomas Ng · MASSACHUSETTS GENERAL HOSPITAL · 2024 · $249,861 — Immune-mediated positron emission tomography (immunoPET) is an emerging imaging technique that enables non-invasive in vivo pathology assessment, analogous to what is commonly used in immunohistology. This is enabled by imaging of radiolabeled antibodies or antibody fragments. However, current immun…
KENNETH E WHITE · INDIANA UNIVERSITY INDIANAPOLIS · 2024 · $431,771 — Abstract: The hallmarks of chronic kidney disease (CKD) include fibrosis, increased inflammatory responses, and dysregulated mineral metabolism, which are all especially problematic in aged patients and strongly associated with morbidity and mortality. Indeed, the fibrotic lesions arising in humans …
Joe L Hsu · STANFORD UNIVERSITY · 2024 · $557,332 — PROJECT SUMMARY/ ABSTRACT This application focuses on the contribution of transplant hemorrhage-induced iron overload in the dysregulation of pulmonary macrophages (mɸs) and the promotion of invasive aspergillosis. Aspergillus fumigatus (Af) is a ubiquitous mold that releases airborne spores (conidi…